A Prospective Clinical Trial to Predict Treatment Response Based on Mutanome-Informed Computational Biology in Patient with AML and MDS

Background: Hypomethylating agents (HMAs) (e.g., azacitidine (aza), decitabine (dec)) and lenalidomide (len) are approved agents and used in the treatment of patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML).